Search results

than two years. Strimvelis is the first ex vivo autologous gene therapy approved by the European Medicines Agency (EMA). Strimvelis is indicated for...

gene therapy drugs were approved, such as alipogene tiparvovec (2012), Strimvelis (2016), tisagenlecleucel (2017), voretigene neparvovec (2017), patisiran...

therapy Strimvelis for rare autoimmune disorder". Seeking Alpha. Retrieved 13 April 2016. "Summary of opinion1 (initial authorisation) Strimvelis" (PDF)...

Revakinagene taroretcel (Encelto): treatment of macular telangiectasia type 2 Strimvelis: treatment for adenosine deaminase deficiency (ADA-SCID) Talimogene laherparepvec...

MolMed partnered with GlaxoSmithKline related to GSK's acquisition of Strimvelis; MolMed had been involved in the early development of the product. In...

addition, he proposed the introduction of specialized medical degrees. Strimvelis: the first ex-vivo stem cell gene therapy to treat patients with a very...

therapy was licensed to GlaxoSmithKline and is marketed under the name Strimvelis, making it the first commercially approved ex vivo gene therapy in Europe...

delivery in at least one step. Hematopoietic stem cell-based gene therapies: Strimvelis for the treatment of adenosine deaminase severe combined immunodeficiency...

planet would have appeared more white than red, the authors say. 27 May – Strimvelis, an ex-vivo stem cell gene therapy for adenosine deaminase deficiency...